Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast reconstruction cases in Kentucky: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (125 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 204 | 37% |
| 2020 | 1 | 169 | 41% |
| 2021 | 0 | 155 | 47% |
| 2022 | 3 | 179 | 52% |
| 2023 | 2 | 182 | 55% |
| 2024 | 1 | 152 | 57% |
| 2025 from claims | – | 115 93–135 | 58% |
| 2026 forecast | – | 115 90–144 | 59% |
| 2027 forecast | – | 115 85–152 | 60% |
| 2028 forecast | – | 115 81–159 | 60% |
| 2029 forecast | – | 115 78–165 | 61% |
| 2030 forecast | – | 115 75–170 | 62% |
Implant- and flap-based reconstruction; ADM and expander call point. Professional codes (what the surgeon bills): CPT 19357, 19340, 19342, 19364, 19380.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Kentucky; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 11 | 1,327−4.8%/yr | −4.8%/yr | 0.6 | 4% | 1,340 in 2030+0.2%/yr |
| Texas | 6 | 1,208−7.1%/yr | −7.1%/yr | 0.6 | 6% | 1,830 in 2030+7.1%/yr |
| Georgia | 1 | 590−6.3%/yr | −6.3%/yr | 0.7 | 0% | 900 in 2030+7.4%/yr |
| Maryland | 1 | 439−4.8%/yr | −4.8%/yr | 0.5 | 0% | 540 in 2030+3.5%/yr |
| Virginia | 3 | 428−9.4%/yr | −9.4%/yr | 0.4 | 0% | 410 in 2030−0.8%/yr |
| Louisiana | 7 | 352+3.9%/yr | +3.9%/yr | 0.9 | 0% | 790 in 2030+14%/yr |
| Tennessee | 3 | 337−11%/yr | −11%/yr | 0.5 | 6% | 470 in 2030+5.5%/yr |
| North Carolina | 0 | 327−13%/yr | −13%/yr | 0.3 | 0% | 330 in 2030−0.1%/yr |
| South Carolina | 1 | 295−3.4%/yr | −3.4%/yr | 0.4 | 0% | 360 in 2030+3.3%/yr |
| Mississippi | 0 | 123−12%/yr | −12%/yr | 0.3 | 58% | 90 in 2030−4.2%/yr |
| Arkansas | 0 | 111−8.5%/yr | −8.5%/yr | 0.3 | 0% | 50 in 2030−13%/yr |
| Oklahoma | 2 | 110−8.8%/yr | −8.8%/yr | 0.2 | 0% | 120 in 2030+1.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cholecystectomy & appendectomy | 56 | 2,519−8.1%/yr | −8.1%/yr | 5.71.3× | 1% | 2,490 in 2030−0.2%/yr |
| Hernia repair | 20 | 2,512−6.9%/yr | −6.9%/yr | 5.80.9× | 1% | 2,530 in 2030+0.1%/yr |
| Colorectal resection | 1 | 825−7.8%/yr | −7.8%/yr | 1.81.1× | 0% | 700 in 2030−2.7%/yr |
| Antireflux & hiatal hernia surgery | 6 | 403−5.9%/yr | −5.9%/yr | 0.91.1× | 0% | 430 in 2030+1%/yr |
| Bariatric surgery | 1 | 103−21%/yr | −21%/yr | 0.21.2× | 0% | 80 in 2030−5.1%/yr |
Breast reconstruction in every state, and its device makers · Every procedure market in Kentucky · Every state · Compare with Florida
Johnson & Johnson MedTech leads with 52% of company spending on these surgeons in 2025, −8 pts on 2024.
In 2025, 7 companies reported engagement with Kentucky’s surgeons worth $55K in consulting, speaking, meals and travel tied to these products, about $55K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.